How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika

How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika

The H1N1 pandemic of 2009-2010, MERS epidemic of 2012, Ebola epidemics of 2013-2016 and 2018-2020, Zika epidemic of 2015-2016, and COVID-19 pandemic of 2019-2021, are recent examples in the long history of epidemics that demonstrate the enormous global impact of viral infection. The rapid developmen...

Full description

Bibliographic Details
Main Authors:	Morgan E. Abernathy, Kim-Marie A. Dam, Shannon R. Esswein, Claudia A. Jette, Pamela J. Bjorkman
Format:	Article
Language:	English
Published:	MDPI AG 2021-10-01
Series:	Viruses
Subjects:	antibody cryo-electron microscopy HIV-1 SARS-CoV-2 structural biology virus
Online Access:	https://www.mdpi.com/1999-4915/13/10/2106

Similar Items

Functional development of a V3/glycan-specific broadly neutralizing antibody isolated from a case of HIV superinfection
by: Mackenzie M Shipley, et al.
Published: (2021-07-01)

Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor
by: Chia, Wan Ni, et al.
Published: (2023)

Rapid detection kit for antibody-antigen recognization for human immunodeficiency virus /
by: Nurul Shahirah Rokman, 1996-, author, et al.
Published: (2019)

Rapid detection kit for antibody-antigen recognization for human immunodeficiency virus /
by: Nurul Shahirah Rokman, 1996-, author
Published: (2019)

A potent anti‐dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface
by: Guntur Fibriansah, et al.
Published: (2014-03-01)

Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV
by: Sarah Wilmschen, et al.
Published: (2019-09-01)

Phage display as a tool for identifying HIV-1 broadly neutralizing antibodies
by: A. N. Chikaev, et al.
Published: (2021-09-01)

Neutralizing Antibodies against Lassa Virus Lineage I
by: Tierra K. Buck, et al.
Published: (2022-08-01)

Rational Design and In Vivo Characterization of mRNA-Encoded Broadly Neutralizing Antibody Combinations against HIV-1
by: Elisabeth Narayanan, et al.
Published: (2022-10-01)

Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core
by: Andrew J Borst, et al.
Published: (2018-11-01)

Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities
by: Yubin Liu, et al.
Published: (2020-01-01)

Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody
by: Wen-Fan Shen, et al.
Published: (2018-10-01)

Cryoelectron microscopy structures of a human neutralizing antibody bound to MERS-CoV spike glycoprotein
by: Shuyuan Zhang, et al.
Published: (2022-09-01)

The structures of secretory and dimeric immunoglobulin A
by: Sonya Kumar Bharathkar, et al.
Published: (2020-10-01)

To prescreen or not to prescreen for broadly neutralizing antibody sensitivity in HIV cure-related trials
by: Hursch Patel, et al.
Published: (2023-09-01)

Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth
by: Deniz Cizmeci, et al.
Published: (2021-04-01)

Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies
by: Garnett Kelsoe, et al.
Published: (2013-12-01)

Myomedin replicas of gp120 V3 loop glycan epitopes recognized by PGT121 and PGT126 antibodies as non-cognate antigens for stimulation of HIV-1 broadly neutralizing antibodies
by: Veronika Daniel Lišková, et al.
Published: (2022-12-01)

An in vitro experimental pipeline to characterize the epitope of a SARS-CoV-2 neutralizing antibody
by: Kristina E. Atanasoff, et al.
Published: (2024-01-01)

Cost‐effectiveness of broadly neutralizing antibody prophylaxis for HIV‐exposed infants in sub‐Saharan African settings
by: Caitlin M. Dugdale, et al.
Published: (2023-01-01)

The Effects of Framework Mutations at the Variable Domain Interface on Antibody Affinity Maturation in an HIV-1 Broadly Neutralizing Antibody Lineage
by: Jeffrey O. Zhou, et al.
Published: (2020-07-01)

Role of framework mutations and antibody flexibility in the evolution of broadly neutralizing antibodies
by: Victor Ovchinnikov, et al.
Published: (2018-02-01)

Antiviral Activities of HIV-1-Specific Human Broadly Neutralizing Antibodies Are Isotype-Dependent
by: Blandine Noailly, et al.
Published: (2022-06-01)

Functional Delineation of a Protein–Membrane Interaction Hotspot Site on the HIV-1 Neutralizing Antibody 10E8
by: Sara Insausti, et al.
Published: (2022-09-01)

Development and characterization of a panel of anti-idiotype antibodies to 1C10 that cross-neutralize HIV-1 subtype B viruses
by: Yu Kaku, et al.
Published: (2022-08-01)

Development and Structural Analysis of Antibody Therapeutics for Filoviruses
by: Xiaoying Yu, et al.
Published: (2022-03-01)

Quaternary Interaction of the HIV-1 Envelope Trimer with CD4 and Neutralizing Antibodies
by: Qingbo Liu, et al.
Published: (2021-07-01)

Passive and active antibody studies in primates to inform HIV vaccines
by: Ann J. Hessell, et al.
Published: (2018-02-01)

Correlation between anti-V3 peptide and neutralizing antibodies in plasma from HIV-1 infected individuals resident in Brazil
by: Vera Bongertz, et al.
Published: (1994-03-01)

Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1
by: Colin LaMont, et al.
Published: (2022-07-01)

SARS-CoV-2 antibodies in adolescents living with perinatally acquired HIV
by: Lisa Frigati, et al.
Published: (2024-03-01)

Computational Characterization of the Binding Properties of the HIV1-Neutralizing Antibody PG16 and Design of PG16-Derived CDRH3 Peptides
by: Manuel Deubler, et al.
Published: (2023-06-01)

Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration
by: Vaneet K. Sharma, et al.
Published: (2020-07-01)

Autoreactivity and broad neutralization of antibodies against HIV-1 are governed by distinct mutations: Implications for vaccine design strategies
by: Xiaojun Li, et al.
Published: (2022-11-01)

Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency
by: Baoshan Zhang, et al.
Published: (2023-12-01)

Which antibody functions are important for an HIV vaccine ?
by: Bin eSu, et al.
Published: (2014-06-01)

Primary HIV-1 and Infectious Molecular Clones Are Differentially Susceptible to Broadly Neutralizing Antibodies
by: Jiae Kim, et al.
Published: (2020-12-01)

«FREE» AND «BOUND» ANTIBODIES AGAINST HIV–1 STRUCTURE PROTEINS AT EARLY STAGE OF THE DISEASE
by: G. A. Rjazanova, et al.
Published: (2014-07-01)

Double and Triple Combinations of Broadly Neutralizing Antibodies Provide Efficient Neutralization of All HIV-1 Strains from the Global Panel
by: Evgeniya A. Kochina, et al.
Published: (2022-08-01)

Are HIV-1-Specific Antibody Levels Potentially Useful Laboratory Markers to Estimate HIV Reservoir Size? A Review
by: Silvere D. Zaongo, et al.
Published: (2021-11-01)